Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.
Commentary|Articles|August 12, 2026
SriniVas R. Sadda, MD, FARVO, on leading Duke Ophthalmology into its next chapter
Author(s)SriniVas R. Sadda, MD, FARVO, Sheryl Stevenson
Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.
Advertisement
Advertisement
As academic medical centers welcome new trainees and faculty for the 2026–2027 academic year,
Related to this article
The Wilmer Eye Institute's new Glaucoma Division chief discusses mentoring junior faculty, multicenter trials, and optic nerve regeneration.
Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.
John A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.
John J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.
Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema.
Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including medication burden and safety.
Drew Carey, MD, and Andrew G. Lee, MD, discuss triage, visual fields, double vision, and cataract topics from Neuro-Ophthalmology Subspecialty Day.
Advertisement
Advertisement